Most Read News


Medical services exported to 20 countries, China, U.S. and Vietnam for the most

The Ministry of Health and Welfare(Minister Jin-Yup Jung) and the Korea Health Industry Development Institute(President Young-Chan Lee) released the analysis result of the ‘2016 Overseas Expansion Status’ on the 6th a...

Korea advanced in global clinical trials, showing 3.41% market share last year

The number of clinical trials is decreasing, but the Korean clinical trial’s market share in the global market was actually increased by approx. 10% to 3.42%. There were changes in ranking as well because of the China...

MOHW, “Administrative measure on Novartis’ rebate will be based on suspension of health insurance benefits”

The Ministry of Health and Welfare(MOHW) stressed the administrative measure on the Novartis’ rebate case would be based on suspension of health insurance benefits. The MOHW said on the 6th that it was reviewing the ...

MOHW, “We’ll consider to relax the criteria for food & beverage in Financial Gain & Expenditure Report”

The Ministry of Health and Welfare(MOHW) was confirmed to positively consider to relax standards for filling up the food & beverage section of the product demonstration in the ‘Financial Gain & Expenditure Report.’ A...

MOHW’s controversial decision over ‘Novartis’ rebate case’

The Ministry of Health and Welfare(MOHW) have many concerns as relevant organizations continue to make pressure of public opinion in regards to the level of administrative measure for the Novartis’ rebate cases. The ...

Pharma & Bio-pharma will revitalize with relieved anxiety and devotion to R&D

The pharmaceutical field will revitalize. The unexpected incident at the end of the last year continued until the beginning of this year, but it seems it is going to be settled soon, which energizes the industry. It...

Growth rate of export was 20% in KOSDAQ, but negative in KOSPI

While pharmaceutical companies in the KOSDAQ showed a large growth in overseas sales & export on average compared to the year before, KOSPI listed pharmaceutical companies recorded a negative value in the growth ratio...

KPDS, “Novartis’ illegality is clear… it is time to explain generics’ safety to patients”

The Korean Pharmacists for Democratic Society(KPDS) urged prompt and strict administrative measures for the Novartis Korea’s rebate case. In the statement on the 12th, the KPDS announced the Ministry of Health and We...

What will be the answers for future new drug development?

What will be the answers for future new drug development? Celgene chose ‘innovation followed by continuous efforts on new drug development’ and ‘active cooperation with various partners.’ In the lecture about ‘Chang...

Oscotec’s FDA-approved clinical trials for treatment of acute myeloid leukemia

Oscotec(CEO Jung-Geun Kim), a new drug development company, announced on the 13th that it made an agreement since the U.S. Phase 1 clinical trial project of the next-generation new drug candidate(SKI-G-801) for the tr...

Amplified anxiety over prosecutors’ investigation in pharma and distribution industry

After the Eastern Branch of Busan District Public Prosecutors’ Office searched and seized influential distribution companies in Seoul and Busan last March, anxiety has been raised among pharmaceutical companies and di...

Celltrion applies sales approval of Herzuma to enter Japanese market

Celltrion announced it applied sales approval of Herzuma(CT-P6, generic name: trastuzumab), a self-developed anticancer antibody biosimilar, at the Japanese Ministry of Health, Labour and Welfare on the 11th to enter ...

Listed pharmas pay KRW 53 million per employee annually

The listed pharmaceutical companies’ average annual salary was KRW 53 million, and Dong-A Socio Holdings recorded the highest KRW 83 million. In addition, the average annual salary for men was KRW 58.56 million, but ...

R&D chiefs from Korean and overseas pharmas will illustrate present and future of ‘open innovation’

The Korea’s largest ‘Open Innovation’ stage will open for the pharmaceutical industry. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association(Chairman Hee-Mok Won) and the Korean Research-based Pharmaceuti...

Regarding delayed report over Olita side effects, Hanmi will do best not to happen again

Regarding the Board of Audit and Inspection’s audit result that it took 14 months for the SJS(Stevens-Johnson syndrome) occurrence to be reported to the Ministry of Food and Drug Safety(MFDS), Hanmi Pharm explained “T...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.